PFDN及其亚基在肿瘤发生发展中的作用

国际肿瘤学杂志››2024,Vol. 51››Issue (6): 350-353.doi:10.3760/cma.j.cn371439-20240218-00060

PFDN及其亚基在肿瘤发生发展中的作用

郭泽浩, 张俊旺()

山西医科大学第二医院消化内科，太原 030000

收稿日期:2024-02-18修回日期:2024-03-10出版日期:2024-06-08发布日期:2024-06-28
通讯作者:张俊旺，Email： jasong@sxmu.edu.cn
基金资助:
山西省自然科学基金(201801D121327)

Role of PFDN and its subunits in tumorigenesis and tumor development

Guo Zehao, Zhang Junwang()

Department of Gastroenterology， Second Hospital of Shanxi Medical University， Taiyuan 030000， China

Received:2024-02-18Revised:2024-03-10Online:2024-06-08Published:2024-06-28
Contact:Zhang Junwang， Email： jasong@sxmu.edu.cn
Supported by:
Natural Science Foundation of Shanxi Province of China(201801D121327)

摘要/Abstract

摘要：

前折叠蛋白（PFDN）作为共伴侣蛋白能够稳定新合成的肽，防止蛋白质错误折叠和聚集，在细胞骨架的形成中发挥重要作用。PFDN在神经胶质瘤、乳腺癌、肺癌、胃癌、肝癌、结直肠癌等多种肿瘤组织中表达上调，与肿瘤细胞的增殖和迁移密切相关。深入了解PFDN在肿瘤发生发展中的作用，可为PFDN在预防或逆转肿瘤进展方面提供新的思路和见解。

郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.

Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.

参考文献27

[1]	Vainberg IE, Lewis SA, Rommelaere H, et al. Prefoldin, a chape-rone that delivers unfolded proteins to cytosolic chaperonin[J].Cell,1998,93(5): 863-873. DOI:10.1016/s0092-8674(00)81446-4. pmid:9630229
[2]	Gestaut D, Roh SH, Ma BX, et al. The chaperonin TRiC/CCT associates with prefoldin through a conserved electrostatic interface essential for cellular proteostasis[J].Cell,2019,177(3): 751-765.e15. DOI:10.1016/j.cell.2019.03.012. pmid:30955883
[3]	Tahmaz I, Shahmoradi Ghahe S, Topf U. Prefoldin function in cellular protein homeostasis and human diseases[J].Front Cell Dev Biol,2021,9: 816214. DOI:10.3389/fcell.2021.816214.
[4]	Wang P, Zhao J, Yang X, et al. PFDN1, an indicator for colorectal cancer prognosis, enhances tumor cell proliferation and motility through cytoskeletal reorganization[J].Med Oncol,2015,32(12): 264. DOI:10.1007/s12032-015-0710-z. pmid:26553318
[5]	Miyazawa M, Tashiro E, Kitaura H, et al. Prefoldin subunits are protected from ubiquitin-proteasome system-mediated degradation by forming complex with other constituent subunits[J].J Biol Chem,2011,286(22): 19191-19203. DOI:10.1074/jbc.M110.216259. pmid:21478150
[6]	Peñate X, Praena-Fernández JM, Romero Pareja P, et al. Over-expression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer[J].Cancers (Basel),2020,12(4): 1052. DOI:10.3390/cancers12041052.
[7]	Zhao HC, Chen CZ, Yang CL, et al. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy[J].Pathol Res Pract,2022,232: 153808. DOI:10.1016/j.prp.2022.153808.
[8]	Jiang LL, Liu J. Prefoldin 6 promotes glioma progression via the AKT signalling pathway[J].Cell Biol Int,2023,47(1): 52-62. DOI:10.1002/cbin.11895.
[9]	Yang KY, Wu ZJ, Zhang H, et al. Glioma targeted therapy: insight into future of molecular approaches[J].Mol Cancer,2022,21(1): 39. DOI:10.1186/s12943-022-01513-z. pmid:35135556
[10]	Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012—2016[J].Neuro Oncol,2019,21(Suppl 5): v1-v100. DOI:10.1093/neuonc/noz150.
[11]	Cai JY, Hu YY, Ye Z, et al. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour micro-environment in lower-grade glioma[J].Front Immunol,2022,13: 1011757. DOI:10.3389/fimmu.2022.1011757.
[12]	Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022[J].CA Cancer J Clin,2022,72(6): 524-541. DOI:10.3322/caac.21754.
[13]	Sarhangi N, Hajjari S, Heydari SF, et al. Breast cancer in the era of precision medicine[J].Mol Biol Rep,2022,49(10): 10023-10037. DOI:10.1007/s11033-022-07571-2. pmid:35733061
[14]	Hashemi M, Arani HZ, Orouei S, et al. EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions[J].Biomed Pharmacother,2022,155: 113774. DOI:10.1016/j.biopha.2022.113774.
[15]	黄超有, 李玺, 韩铮, 等. Prefoldin 1对乳腺癌BT474细胞上皮-间充质转化的影响[J].实用医学杂志,2019,35(1): 47-50. DOI:10.3969/j.issn.1006-5725.2019.01.010.
[16]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660.
[17]	Li YT, Yan BS, He SM. Advances and challenges in the treatment of lung cancer[J].Biomed Pharmacother,2023,169: 115891. DOI:10.1016/j.biopha.2023.115891.
[18]	Wang D, Shi W, Tang Y, et al. Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression[J].Oncogene,2017,36(7): 885-898. DOI:10.1038/onc.2016.257. pmid:27694898
[19]	Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives[J].J Hematol Oncol,2023,16(1): 57. DOI:10.1186/s13045-023-01451-3.
[20]	于晓鹏, 冯青青, 赵文飞, 等. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J].国际肿瘤学杂志,2023,50(10): 631-635. DOI:10.3760/cma.j.cn371439-20230428-00120.
[21]	Zhou C, Guo ZY, Xu LQ, et al. PFND1 predicts poor prognosis of gastric cancer and promotes cell metastasis by activating the Wnt/β-catenin pathway[J].Onco Targets Ther,2020,13: 3177-3186. DOI:10.2147/OTT.S236929.
[22]	Malagoli Tagliazucchi G, Wiecek AJ, Withnell E, et al. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer[J].Nat Commun,2023,14(1): 789. DOI:10.1038/s41467-023-36439-7. pmid:36774358
[23]	Chen TN, He QM, Xiang ZX, et al. Identification and validation of key genes of differential correlations in gastric cancer[J].Front Cell Dev Biol,2021,9: 801687. DOI:10.3389/fcell.2021.801687.
[24]	He QM, Ding ZY, Chen TN, et al. PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer[J].Front Oncol,2023,13: 1164070. DOI:10.3389/fonc.2023.1164070.
[25]	Shao YF, Yesseyeva G, Zhi YH, et al. Comprehensive multi-omics analysis and experimental verification reveal PFDN5 is a novel prognostic and therapeutic biomarker for gastric cancer[J].Genomics,2024,116(2): 110821. DOI:10.1016/j.ygeno.2024.110821.
[26]	Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches[J].Biochim Biophys Acta Rev Cancer,2020,1873(1):188314. DOI:10.1016/j.bbcan.2019.188314.
[27]	Ke SJ, Lu SN, Wang CQ, et al. Comprehensive analysis of the prognostic value and functions of prefoldins in hepatocellular carcinoma[J].Front Mol Biosci,2022,9: 957001. DOI:10.3389/fmolb.2022.957001.

PFDN及其亚基在肿瘤发生发展中的作用

Role of PFDN and its subunits in tumorigenesis and tumor development

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献27

相关文章15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[6]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[7]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[8]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[9]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[10]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[11]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[12]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[13]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[14]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[15]	傅旖, 马辰莺, 张露, 周菊英.生境分析在恶性肿瘤影像组学中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 292-297.